Puma Biotechnology, INC Form 4 insider transactions

Alan H. Auerbach, Director, President and CEO of Puma Biotechnology, Inc., reported a transaction involving the sale of common stock.

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, Inc., reported a transaction involving the sale of common stock.

Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, reported the sale of 9,386 shares of common stock on July 6, 2026, under a pre-arranged 10b5-1 trading plan.

Director Troy E. Wilson acquired 27,000 restricted stock units and sold 10,800 shares of Puma Biotechnology common stock.

Director Brian M. Stuglik acquired 27,000 restricted stock units and sold 8,100 shares of Puma Biotechnology common stock.

Director Adrian Senderowicz acquired 27,000 restricted stock units and subsequently sold 27,000 shares of Puma Biotechnology common stock.

Director Michael Patrick Miller was granted 27,000 restricted stock units in Puma Biotechnology, Inc.

Director Jay M. Moyes acquired 27,000 restricted stock units and subsequently sold 22,000 shares of common stock.

Director Allison Dorval acquired 27,000 restricted stock units and sold 11,610 shares of Puma Biotechnology common stock.

Director Alessandra Cesano was granted 27,000 restricted stock units in Puma Biotechnology, Inc.

Puma Biotechnology's President and CEO, Alan H. Auerbach, received significant grants of Restricted Stock Units and stock options, vesting over the next two years.

Puma Biotechnology's Senior VP of Regulatory Affairs, Douglas M. Hunt, was granted 49,394 Restricted Stock Units and 70,321 stock options, vesting over two years.

Puma Biotechnology's CFO, Maximo F. Nougues, received 46,739 Restricted Stock Units and 66,541 stock options as part of his compensation.

Puma Biotechnology's President and CEO, Alan H. Auerbach, sold 34,950 shares of common stock for approximately $204,000 through a pre-arranged 10b5-1 trading plan.

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 8,987 shares of common stock in early January 2026 through a pre-arranged 10b5-1 trading plan.

Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, sold a total of 10,945 shares of common stock in early January 2026 under a pre-arranged 10b5-1 trading plan.

Puma Biotechnology Director Michael Patrick Miller sold 20,000 shares of common stock for approximately $4.86 per share on November 11, 2025, under a Rule 10b5-1 plan.

Puma Biotechnology Director Alessandra Cesano sold 27,000 shares of common stock for a weighted average price of $3.367 per share, reducing her direct beneficial ownership to 41,850 shares.

Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, sold a total of 9,522 shares of common stock over two days in July 2025, pursuant to a Rule 10b5-1 trading plan.

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, Inc., sold 7,817 shares of common stock in two transactions in early July 2025, pursuant to a Rule 10b5-1 trading plan.

Puma Biotechnology's President and CEO, Alan H. Auerbach, sold a total of 47,172 shares of common stock in early July 2025 under a pre-arranged Rule 10b5-1 trading plan.

Troy Edward Wilson, a Director at Puma Biotechnology, Inc. (PBYI), sold 10,800 shares of common stock on June 13, 2025, through a pre-arranged 10b5-1 trading plan.

Brian M. Stuglik, a Director at Puma Biotechnology, Inc., sold 8,100 shares of common stock for approximately $3.39 per share under a Rule 10b5-1 trading plan.

A director at Puma Biotechnology, Adrian Senderowicz, sold 27,000 shares of common stock for approximately $91,800 under a pre-arranged 10b5-1 trading plan.

Jay M. Moyes, a Director at Puma Biotechnology, Inc., sold 22,000 shares of common stock for approximately $3.4 per share on June 13, 2025, pursuant to a Rule 10b5-1 trading plan.

Allison Dorval, a Director at Puma Biotechnology, Inc., sold 11,610 shares of common stock for approximately $3.4 per share on June 13, 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Alessandra Cesano, a Director at Puma Biotechnology, Inc., sold 12,150 shares of common stock for approximately $41,310 on June 13, 2025, as part of a pre-scheduled trading plan.

Puma Biotechnology, Inc. Director Michael Patrick Miller was granted 27,000 shares of common stock in the form of Restricted Stock Units, increasing his direct beneficial ownership to 74,000 shares.

Puma Biotechnology, Inc. Director Adrian Senderowicz has acquired 27,000 Restricted Stock Units (RSUs), increasing his beneficial ownership to 54,000 shares.

Puma Biotechnology, Inc. Director Jay M. Moyes acquired 27,000 shares of common stock through a Restricted Stock Unit grant on June 11, 2025, increasing his beneficial ownership to 75,322 shares.